The headquarter of the European Medicines Agency, London
Market Herald logo


Be the first with the news that moves the market
  • Alterity has been given a positive opinion from the European Medicines Agency for its multiple system atrophy treatment drug
  • The support means the treatment is one step closer to gaining orphan drug status in Europe
  • Orphan drugs are designed to treat diseases so rare they would not bring in a profit without some government assistance
  • Alterity’s share price is up 12.5 per cent in mid-afternoon trade, worth 2.7 cents per share

Alterity’s multiple system atrophy (MSA) treatment has received some positive backing from the European Medicines Agency.

The agency’s Committee for Orphan Medicinal Products (COMP) gave the PBT434 drug a positive opinion to the European Commission (EC) on designating the treatment as an orphan medicinal product.

Essentially, orphan status refers to a drug designed to treat a condition so rare it would not be profitable to produce the drug without government assistance.

In Alterity’s case, it’s PBT434 molecule was proven to be a safe and tolerable treatment for MSA and Parkinson’s disease during a Phase 1 clinical trial in July.

Today’s backing means the treatment is one step closer to gaining orphan drug status in Europe and subsequent government backing.

Alterity CEO Geoffrey Kempler said the positive opinion from COMP is good news for future company expansion plans.

“Europe is a key market for Alterity, and it will lay the foundation for the Company to expand the use of PBT434 into other markets,” Geoffrey said.

“We look forward to hearing more from the EC on their decision and will keep our stakeholders updated on progress,” he said.

MSA is a neurological disease with similar symptoms to Parkinson’s. Sufferers often experience tremors, muscle rigidity, loss of full bodily control, and postural instability.

Alterity’s PBT434 was granted orphan drug status from the U.S. Food and Drug Administration (FDA) for the treatment of MSA.

After today’s injection of confidence, it’s now up to the EC to decide whether it will follow the FDA’s footsteps and recommend the drug for the same status in Europe.

Alterity’s shares are up 12.5 per cent in mid-afternoon trade, worth 2.7 cents each in a $23.46 million market cap.

ATH by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.